Detection of p53 polymorphism at codon 72 by PCR and allele-specific oligonucleotide hybridization on microtiter plates

Clinical Chemistry

Volumn 46, Issue 1, 2000, Pages 124-126

  Tong, Dan ^a   Kucera, Elisabeth ^a   Stimpfl, Margit ^a   Kölbl, Heinz ^a   Leodolter, Sepp ^a,b   Zeillinger, Robert ^a,c  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^c UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; OLIGONUCLEOTIDE; PROTEIN P53;

ADULT; AGED; ALLELE; ARTICLE; CODON; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; HUMAN; HUMAN CELL; HYBRIDIZATION; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE;

EID: 0033950786     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/46.1.124     Document Type: Article

References (18)

1. 1. Baker SJ, Markowitz S, Fearon ER, Willson JK, Vogelstein B. Suppression of human colorectal carcinoma cell growth by wild type p53. Science 1990; 249:912-5.
2. 2. Finlay CA, Hinds PW, Levine AJ. The p53 proto-oncogene can act as a suppressor of transformation. Cell 1989;57:1083-93.
3. 3. Vogelstein B. Cancer. A deadly inheritance. Nature 1990;348:681-2.
4. 4. Milner J, Medcalf EA. Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation. Cell 1991; 65:765-74.
5. 5. Matlashewski GJ, Tuck S, Pim D, Lamb P, Schneider J, Crawford LV. Primary structure polymorphism at amino acid residue 72 of human p53. Mol Cell Biol 1987;7:961-3.
6. 6. Beckman G, Birgander R, Själander A, Saha N, Holmberg PA, Kivelä A, et al. Is p53 polymorphism maintained by nature selection? Hum Hered 1994;44: 266-70.
7. 7. Själander A, Birgander R, Saha N, Beckman L, Beckman G. p53 polymorphisms and haplotypes show distinct differences between major ethnic groups. Hum Hered 1996:46:41-8.
8. 8. Birgander R, Själander A, Zhou Z, Fan C, Beckman L, Beckman G. p53 polymorphisms and haplotypes in nasopharyngeal cancer. Hum Hered 1996;46:49-54.
9. 9. Buller RE, Sood A, Fullenkamp C, Sorosky J, Powills K, Anderson B. The influence of the p53 codon 72 polymorphism on ovarian carcinogenesis and prognosis. Cancer Gene Ther 1997;4:239-45.
10. 10. Kawajiri K, Nakachi K, Imai K, Watanabe J, Hayashi S. Germ line polymorphisms of p53 and CYP1A1 genes involved in human lung cancer. Carcinogenesis 1993;14:1085-9.
11. 11. Sarnow P, Ho YS, Williams J, Levine AJ. Adenovirus E1b-58kd tumor antigen and SV40 large tumor antigen are physically associated with the same 54 cellular protein in transformed cells. Cell 1982;28:387-94.
12. 12. Werness BA, Levine AJ, Howley PM. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 1990;248:76-9.
13. 13. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990;63:1129-36.
14. 14. Storey A, Thomas M, Kalita A, Harwood C, Gardiol D, Mantovani F, et al. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature 1998;393:229-34.
15. 15. Minaguchi T, Kanamori Y, Matsushima M, Yoshikawa H, Taketani Y, Nakamura Y. No evidence of correlation between polymorphism at codon 72 of p53 and risk of cervical cancer in Japanese patients with human papillomavirus 16/18 infection. Cancer Res 1998;58:4585-6.
16. 16. Rosenthal AN, Ryan A, Al-Jehani RM, Storey A, Harwood CA, Jacobs IJ. p53 codon 72 polymorphism and risk of cervical cancer in UK. Lancet 1998; 352:871-2.
17. 17. Helland A, Holm R, Kristensen G, Kaern J, Karlsen F, Trope C, et al. Genetic alterations of the TP53 gene, p53 protein expression and HPV infection in primary cervical carcinomas. J Pathol 1993;171:105-14.
18. 18. Mullokandov MR, Kholodilov NG, Atkin NB, Burk RD, Johnson AB, Klinger HP. Genomic alterations in cervical carcinoma: losses of chromosome heterozygosity and human papilloma virus tumor status. Cancer Res 1996;56:197-205.